In addition, isocitrate dehydrogenase (IDH) and bromodomain and extraterminal (BET) inhibitors have also been reported in the treatment of myeloid neoplasms (107, 108), and further studies should be carried out to elucidate the role of IDH and BET inhibitors in the HSCT setting. Here, DNER is linked to myeloid neoplasm.